B-cell lymphoma historical perspective: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
Line 9: Line 9:
**In 1838, Richard Bright was the first to discover the association between [[spleen]] and HL.
**In 1838, Richard Bright was the first to discover the association between [[spleen]] and HL.
**In 1865, Samuel Wilks honored Thomas Hodgkin by referring this disease as Hodgkin's lymphoma in his publication which he observed and described similar cases since 1856.
**In 1865, Samuel Wilks honored Thomas Hodgkin by referring this disease as Hodgkin's lymphoma in his publication which he observed and described similar cases since 1856.
**Langhans and Greenfield first described the [[microscopic]] characteristics of HL in 1872 and 1878, respectively.  
**Langhans and Greenfield first described HL's [[microscopic]] characteristics in 1872 and 1878, respectively.  
**In 1898 and 1902, Carl Sternberg and Dorothy Reed, respectively, made important contributions to the microscopy of HL. One of these contributions was describing Reed-Sternberg (R-S) cells, which are the hallmark tumor cells of HL.
**In 1898 and 1902, Carl Sternberg and Dorothy Reed, respectively, made important contributions to the microscopy of HL. One of these contributions was describing Reed-Sternberg (R-S) cells, which are the hallmark tumor cells of HL.
**In 1944, Hodgkin’s lymphoma was classified by Jackson and Parker into three subtypes: paragranuloma, granuloma, and sarcoma.<ref name="pmid5776548">{{cite journal |vauthors=Cross RM |title=Hodgkin's disease: histological classification and diagnosis |journal=J Clin Pathol |volume=22 |issue=2 |pages=165–82 |date=March 1969 |pmid=5776548 |pmc=474028 |doi=10.1136/jcp.22.2.165 |url=}}</ref>
**In 1944, Hodgkin’s lymphoma was classified by Jackson and Parker into three subtypes: paragranuloma, granuloma, and sarcoma.<ref name="pmid5776548">{{cite journal |vauthors=Cross RM |title=Hodgkin's disease: histological classification and diagnosis |journal=J Clin Pathol |volume=22 |issue=2 |pages=165–82 |date=March 1969 |pmid=5776548 |pmc=474028 |doi=10.1136/jcp.22.2.165 |url=}}</ref>
Line 19: Line 19:
**In 1864, Virchow, a German physician, had described the [[pathologic]] enlargement of [[lymph nodes]] as lymphosarcoma.
**In 1864, Virchow, a German physician, had described the [[pathologic]] enlargement of [[lymph nodes]] as lymphosarcoma.
**In 1865, Cohnheim, a German-Jewish physician, had described the pathologic enlargement of lymph nodes and spleen as pseudoleukaemia.
**In 1865, Cohnheim, a German-Jewish physician, had described the pathologic enlargement of lymph nodes and spleen as pseudoleukaemia.
**The term ‘malignant lymphoma’ was first coined by Bilroth, a Prussian-born Austrian [[surgeon]], in 1871.
**The term ‘malignant lymphoma’ was first coined by Billroth, a Prussian-born Austrian [[surgeon]], in 1871.
**In 1956, Henry Rappaport provided the first organized classification of [[Non-Hodgkin lymphoma|non-Hodgkin lymphomas]], which modified by the Armed Forces Institute of Pathology, in 1966.
**In 1956, Henry Rappaport provided the first organized classification of [[Non-Hodgkin lymphoma|non-Hodgkin lymphomas]], which was modified by the Armed Forces Institute of Pathology, in 1966.
**[[Burkitt lymphoma]] (a subtype of NHL) was first discovered by [[Denis Parsons Burkitt]], an Irish [[surgeon]], in 1958, during his work in Africa.<ref name="pmid27681061">{{cite journal |vauthors=Esau D |title=Denis Burkitt: A legacy of global health |journal=J Med Biogr |volume=27 |issue=1 |pages=4–8 |date=February 2019 |pmid=27681061 |doi=10.1177/0967772016658785 |url=}}</ref>
**[[Burkitt lymphoma]] (a subtype of NHL) was first discovered by [[Denis Parsons Burkitt]], an Irish [[surgeon]], in 1958, during his work in Africa.<ref name="pmid27681061">{{cite journal |vauthors=Esau D |title=Denis Burkitt: A legacy of global health |journal=J Med Biogr |volume=27 |issue=1 |pages=4–8 |date=February 2019 |pmid=27681061 |doi=10.1177/0967772016658785 |url=}}</ref>
**In 1974, Lukes and Collins provided a new classification system of NHL according to the site of origin, state of transformation, and predominant cell of origin ([[B cell]], [[T cell]], or [[histiocyte]]).<ref name="pmid26355399">{{cite journal |vauthors=Lakhtakia R, Burney I |title=A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma |journal=Sultan Qaboos Univ Med J |volume=15 |issue=3 |pages=e317–21 |date=August 2015 |pmid=26355399 |pmc=4554264 |doi=10.18295/squmj.2015.15.03.003 |url=}}</ref>
**In 1974, Lukes and Collins provided a new classification system of NHL according to the site of origin, state of transformation, and predominant cell of origin ([[B cell]], [[T cell]], or [[histiocyte]]).<ref name="pmid26355399">{{cite journal |vauthors=Lakhtakia R, Burney I |title=A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma |journal=Sultan Qaboos Univ Med J |volume=15 |issue=3 |pages=e317–21 |date=August 2015 |pmid=26355399 |pmc=4554264 |doi=10.18295/squmj.2015.15.03.003 |url=}}</ref>
Line 27: Line 27:
**In 2001, 2008, and 2016, [[World Health Organization]] ([[World Health Organization|WHO]]) provided revised classifications of NHL, based on the REAL classification.<ref name="pmid16098289">{{cite journal |vauthors=Lu P |title=Staging and classification of lymphoma |journal=Semin Nucl Med |volume=35 |issue=3 |pages=160–4 |date=July 2005 |pmid=16098289 |doi=10.1053/j.semnuclmed.2005.02.002 |url=}}</ref><ref name="pmid11754390">{{cite journal |vauthors=Chan JK |title=The new World Health Organization classification of lymphomas: the past, the present and the future |journal=Hematol Oncol |volume=19 |issue=4 |pages=129–50 |date=December 2001 |pmid=11754390 |doi=10.1002/hon.660 |url=}}</ref><ref name="pmid20008237">{{cite journal |vauthors=Jaffe ES |title=The 2008 WHO classification of lymphomas: implications for clinical practice and translational research |journal=Hematology Am Soc Hematol Educ Program |volume= |issue= |pages=523–31 |date=2009 |pmid=20008237 |pmc=6324557 |doi=10.1182/asheducation-2009.1.523 |url=}}</ref><ref name="pmid26980727">{{cite journal |vauthors=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES |title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms |journal=Blood |volume=127 |issue=20 |pages=2375–90 |date=May 2016 |pmid=26980727 |pmc=4874220 |doi=10.1182/blood-2016-01-643569 |url=}}</ref>
**In 2001, 2008, and 2016, [[World Health Organization]] ([[World Health Organization|WHO]]) provided revised classifications of NHL, based on the REAL classification.<ref name="pmid16098289">{{cite journal |vauthors=Lu P |title=Staging and classification of lymphoma |journal=Semin Nucl Med |volume=35 |issue=3 |pages=160–4 |date=July 2005 |pmid=16098289 |doi=10.1053/j.semnuclmed.2005.02.002 |url=}}</ref><ref name="pmid11754390">{{cite journal |vauthors=Chan JK |title=The new World Health Organization classification of lymphomas: the past, the present and the future |journal=Hematol Oncol |volume=19 |issue=4 |pages=129–50 |date=December 2001 |pmid=11754390 |doi=10.1002/hon.660 |url=}}</ref><ref name="pmid20008237">{{cite journal |vauthors=Jaffe ES |title=The 2008 WHO classification of lymphomas: implications for clinical practice and translational research |journal=Hematology Am Soc Hematol Educ Program |volume= |issue= |pages=523–31 |date=2009 |pmid=20008237 |pmc=6324557 |doi=10.1182/asheducation-2009.1.523 |url=}}</ref><ref name="pmid26980727">{{cite journal |vauthors=Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES |title=The 2016 revision of the World Health Organization classification of lymphoid neoplasms |journal=Blood |volume=127 |issue=20 |pages=2375–90 |date=May 2016 |pmid=26980727 |pmc=4874220 |doi=10.1182/blood-2016-01-643569 |url=}}</ref>
===Landmark Events in the Development of Treatment Strategies===
===Landmark Events in the Development of Treatment Strategies===
*Landmark events in the development of treatment strategies for Hodgkin's lymphoma include:
**In 1832, treatment of [[Hodgkin's lymphoma]] (HL) was first tried by Thomas Hodgkin. However, there was no improvement seen with this treatment according to the [[autopsy]] findings.<ref name="pmid26052452">{{cite journal |vauthors=Lakhtakia R, Burney I |title=A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma |journal=Sultan Qaboos Univ Med J |volume=15 |issue=2 |pages=e202–6 |date=May 2015 |pmid=26052452 |pmc=4450782 |doi= |url=}}</ref>
**The first satisfactory treatment of HL was first time reported in 1894 using Fowler's solution, which was based on potassium arsenite.<ref name="pmid26052452">{{cite journal |vauthors=Lakhtakia R, Burney I |title=A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma |journal=Sultan Qaboos Univ Med J |volume=15 |issue=2 |pages=e202–6 |date=May 2015 |pmid=26052452 |pmc=4450782 |doi= |url=}}</ref><ref name="pmid11331434">{{cite journal |vauthors=Waxman S, Anderson KC |title=History of the development of arsenic derivatives in cancer therapy |journal=Oncologist |volume=6 Suppl 2 |issue= |pages=3–10 |date=2001 |pmid=11331434 |doi=10.1634/theoncologist.6-suppl_2-3 |url=}}</ref><ref name="pmid12012319">{{cite journal |vauthors=Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ |title=Expanding the use of arsenic trioxide: leukemias and beyond |journal=Semin Hematol |volume=39 |issue=2 Suppl 1 |pages=22–6 |date=April 2002 |pmid=12012319 |doi=10.1053/shem.2002.33611 |url=}}</ref>
**In 1902, William A. Pusey, an American physician, used [[radiotherapy]] for the treatment of HL.<ref name="pmid12930382">{{cite journal |vauthors=DeVita VT |title=A selective history of the therapy of Hodgkin's disease |journal=Br J Haematol |volume=122 |issue=5 |pages=718–27 |date=September 2003 |pmid=12930382 |doi=10.1046/j.1365-2141.2003.04541.x |url=}}</ref>
**In the 1920s and 1950s, Gilbert and Peters, respectively, proposed the pattern of contiguous spread of lymph nodes in HL.<ref name="pmid12930382">{{cite journal |vauthors=DeVita VT |title=A selective history of the therapy of Hodgkin's disease |journal=Br J Haematol |volume=122 |issue=5 |pages=718–27 |date=September 2003 |pmid=12930382 |doi=10.1046/j.1365-2141.2003.04541.x |url=}}</ref>
**In the 1940s, [[nitrogen mustard]] therapy was announced as a new treatment option for HL by Goodman et al..<ref name="pmid20997191">{{cite journal |vauthors=GOODMAN LS, WINTROBE MM |title=Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders |journal=J Am Med Assoc |volume=132 |issue= |pages=126–32 |date=September 1946 |pmid=20997191 |doi=10.1001/jama.1946.02870380008004 |url=}}</ref>
**In 1966 and 1973, Peters and Kaplan, respectively, applied appropriate radiotherapy according to the patterns of spread.<ref name="pmid12930382">{{cite journal |vauthors=DeVita VT |title=A selective history of the therapy of Hodgkin's disease |journal=Br J Haematol |volume=122 |issue=5 |pages=718–27 |date=September 2003 |pmid=12930382 |doi=10.1046/j.1365-2141.2003.04541.x |url=}}</ref>
**


===Impact on Cultural History===
===Impact on Cultural History===

Revision as of 12:48, 12 January 2022

B-cell lymphoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating B-cell lymphoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

B-cell lymphoma historical perspective On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of B-cell lymphoma historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on B-cell lymphoma historical perspective

CDC on B-cell lymphoma historical perspective

B-cell lymphoma historical perspective in the news

Blogs on B-cell lymphoma historical perspective

Directions to Hospitals Treating B-cell lymphoma

Risk calculators and risk factors for B-cell lymphoma historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Adnan Ezici, M.D[2]

Overview

Historical Perspective

Discovery

  • B-cell lymphomas include both Hodgkin's lymphoma and most Non-Hodgkin lymphoma. Historical landmarks of the discovery of Hodgkin's lymphoma include:[1]
    • Hodgkin's lymphoma (HL) was first discovered by Thomas Hodgkin, a British physician, in 1832. However, a prior description for HL was provided by Marcello Malpighi, an Italian physician, in 1666.
    • In 1838, Richard Bright was the first to discover the association between spleen and HL.
    • In 1865, Samuel Wilks honored Thomas Hodgkin by referring this disease as Hodgkin's lymphoma in his publication which he observed and described similar cases since 1856.
    • Langhans and Greenfield first described HL's microscopic characteristics in 1872 and 1878, respectively.
    • In 1898 and 1902, Carl Sternberg and Dorothy Reed, respectively, made important contributions to the microscopy of HL. One of these contributions was describing Reed-Sternberg (R-S) cells, which are the hallmark tumor cells of HL.
    • In 1944, Hodgkin’s lymphoma was classified by Jackson and Parker into three subtypes: paragranuloma, granuloma, and sarcoma.[2]
    • In 1966, Lukes and Butler proposed a new classification based on the predominant histopathologic type of the disease into six groups: lymphocytic and/or histiocytic, nodular; lymphocytic and/or histiocytic, diffuse; nodular sclerosis; mixed; diffuse fibrosis, and reticular. They also strengthened this classification by suggesting that there was a 'definite relationship between the histological findings, clinical stages, and survival'. In 1966, at the Rye symposium, those 6 types modified into 4 types as lymphocytic predominance (includes both previous types of lymphocytic and/or histiocytic, nodular; lymphocytic and/or histiocytic, diffuse), nodular sclerosis, mixed cellularity, and lymphocytic depletion (includes both previous types of diffuse fibrosis and reticular).[1][2][3]
    • In 1994, the Revised European-American Lymphoma Classification proposed a new classification system and classified Hodgkin’s lymphoma into two main types: nodular lymphocyte predominant Hodgkin’s lymphoma and classical Hodgkin’s lymphoma (includes lymphocyte predominant, nodular sclerosis, mixed cellularity, and lymphocyte depleted).[4]
    • In 2001 and 2008 World Health Organization (WHO) classification provided a new subtype of classical Hodgkin lymphoma, lymphocyte-rich classical Hodgkin lymphoma, which replaced the previous type of lymphocytic predominance classical Hodgkin lymphoma. [5][6]
    • In 2016, the latest revision of classification of Hodgkin lymphoma was made by World Health Organisation (WHO).[7]
  • Historical landmarks of the discovery of non-Hodgkin lymphoma (NHL) include:[8]
    • In 1864, Virchow, a German physician, had described the pathologic enlargement of lymph nodes as lymphosarcoma.
    • In 1865, Cohnheim, a German-Jewish physician, had described the pathologic enlargement of lymph nodes and spleen as pseudoleukaemia.
    • The term ‘malignant lymphoma’ was first coined by Billroth, a Prussian-born Austrian surgeon, in 1871.
    • In 1956, Henry Rappaport provided the first organized classification of non-Hodgkin lymphomas, which was modified by the Armed Forces Institute of Pathology, in 1966.
    • Burkitt lymphoma (a subtype of NHL) was first discovered by Denis Parsons Burkitt, an Irish surgeon, in 1958, during his work in Africa.[9]
    • In 1974, Lukes and Collins provided a new classification system of NHL according to the site of origin, state of transformation, and predominant cell of origin (B cell, T cell, or histiocyte).[8]
    • Mantle cell lymphoma (MCL) was first discovered by Banks, in 1992.[10]
    • In 1994, the Revised European-American Classification of Lymphoid Neoplasms (REAL) classified non-Hodgkin's lymphoma according to the clinical features, immunology and genetic information.[4]
    • In 2001, 2008, and 2016, World Health Organization (WHO) provided revised classifications of NHL, based on the REAL classification.[11][5][6][7]

Landmark Events in the Development of Treatment Strategies

  • Landmark events in the development of treatment strategies for Hodgkin's lymphoma include:
    • In 1832, treatment of Hodgkin's lymphoma (HL) was first tried by Thomas Hodgkin. However, there was no improvement seen with this treatment according to the autopsy findings.[1]
    • The first satisfactory treatment of HL was first time reported in 1894 using Fowler's solution, which was based on potassium arsenite.[1][12][13]
    • In 1902, William A. Pusey, an American physician, used radiotherapy for the treatment of HL.[14]
    • In the 1920s and 1950s, Gilbert and Peters, respectively, proposed the pattern of contiguous spread of lymph nodes in HL.[14]
    • In the 1940s, nitrogen mustard therapy was announced as a new treatment option for HL by Goodman et al..[15]
    • In 1966 and 1973, Peters and Kaplan, respectively, applied appropriate radiotherapy according to the patterns of spread.[14]

Impact on Cultural History

Famous Cases

References

  1. ↑ 1.0 1.1 1.2 1.3 Lakhtakia R, Burney I (May 2015). "A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma". Sultan Qaboos Univ Med J. 15 (2): e202–6. PMC 4450782. PMID 26052452.
  2. ↑ 2.0 2.1 Cross RM (March 1969). "Hodgkin's disease: histological classification and diagnosis". J Clin Pathol. 22 (2): 165–82. doi:10.1136/jcp.22.2.165. PMC 474028. PMID 5776548.
  3. ↑ Lukes RJ, Butler JJ (June 1966). "The pathology and nomenclature of Hodgkin's disease". Cancer Res. 26 (6): 1063–83. PMID 5947336.
  4. ↑ 4.0 4.1 Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC (September 1994). "A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group". Blood. 84 (5): 1361–92. PMID 8068936.
  5. ↑ 5.0 5.1 Chan JK (December 2001). "The new World Health Organization classification of lymphomas: the past, the present and the future". Hematol Oncol. 19 (4): 129–50. doi:10.1002/hon.660. PMID 11754390.
  6. ↑ 6.0 6.1 Jaffe ES (2009). "The 2008 WHO classification of lymphomas: implications for clinical practice and translational research". Hematology Am Soc Hematol Educ Program: 523–31. doi:10.1182/asheducation-2009.1.523. PMC 6324557. PMID 20008237.
  7. ↑ 7.0 7.1 Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES (May 2016). "The 2016 revision of the World Health Organization classification of lymphoid neoplasms". Blood. 127 (20): 2375–90. doi:10.1182/blood-2016-01-643569. PMC 4874220. PMID 26980727.
  8. ↑ 8.0 8.1 Lakhtakia R, Burney I (August 2015). "A Historical Tale of Two Lymphomas: Part II: Non-Hodgkin lymphoma". Sultan Qaboos Univ Med J. 15 (3): e317–21. doi:10.18295/squmj.2015.15.03.003. PMC 4554264. PMID 26355399.
  9. ↑ Esau D (February 2019). "Denis Burkitt: A legacy of global health". J Med Biogr. 27 (1): 4–8. doi:10.1177/0967772016658785. PMID 27681061.
  10. ↑ Banks PM, Chan J, Cleary ML, Delsol G, De Wolf-Peeters C, Gatter K, Grogan TM, Harris NL, Isaacson PG, Jaffe ES (July 1992). "Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data". Am J Surg Pathol. 16 (7): 637–40. doi:10.1097/00000478-199207000-00001. PMID 1530105.
  11. ↑ Lu P (July 2005). "Staging and classification of lymphoma". Semin Nucl Med. 35 (3): 160–4. doi:10.1053/j.semnuclmed.2005.02.002. PMID 16098289.
  12. ↑ Waxman S, Anderson KC (2001). "History of the development of arsenic derivatives in cancer therapy". Oncologist. 6 Suppl 2: 3–10. doi:10.1634/theoncologist.6-suppl_2-3. PMID 11331434.
  13. ↑ Chen Z, Chen GQ, Shen ZX, Sun GL, Tong JH, Wang ZY, Chen SJ (April 2002). "Expanding the use of arsenic trioxide: leukemias and beyond". Semin Hematol. 39 (2 Suppl 1): 22–6. doi:10.1053/shem.2002.33611. PMID 12012319.
  14. ↑ 14.0 14.1 14.2 DeVita VT (September 2003). "A selective history of the therapy of Hodgkin's disease". Br J Haematol. 122 (5): 718–27. doi:10.1046/j.1365-2141.2003.04541.x. PMID 12930382.
  15. ↑ GOODMAN LS, WINTROBE MM (September 1946). "Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders". J Am Med Assoc. 132: 126–32. doi:10.1001/jama.1946.02870380008004. PMID 20997191.


Template:WikiDoc Sources

Retrieved from "https://www.wikidoc.org/index.php?title=B-cell_lymphoma_historical_perspective&oldid=1718542"